Inhalation injury and pulmonary management

Overview

Inhalation injury is the dominant cause of in-hospital death after major burn injury in the modern era. The reduction in mortality from burn shock and from invasive wound sepsis over the past five decades has not been matched by an equivalent improvement in pulmonary outcomes, and inhalation injury has now become the most frequent cause of death in burn patients ^[1]. Smoke inhalation alone carries a low isolated mortality (0 to 11 percent), but the combination of cutaneous burn with inhalation injury is fatal in 30 to 90 percent of patients ^[1]. The fundamental clinical problem is that smoke produces three superimposed insults — upper-airway thermal injury, lower-airway chemical injury from particulate and gaseous combustion products, and systemic toxin delivery from carbon monoxide and cyanide — and each demands a different therapeutic response [2, 15, 90].

The pathophysiology is well characterized in ovine models but remains incompletely translated. Therapy is overwhelmingly supportive: no antidote exists for the damaging effects of smoke toxicants on pulmonary tissue, and improvements in mortality from inhalation injury are mostly due to advances in critical care rather than focused interventions for smoke inhalation [16, 85]. Within that supportive frame, four management decisions matter most — when to intubate, how to ventilate, what to nebulize, and whether to treat cyanide empirically — and each is treated below.

Epidemiology

Inhalation injury occurs in roughly one-third of patients admitted to major burn centers. Across a 12-year cohort of 231 critically ill burn patients, 36 percent had bronchoscopically diagnosed inhalation injury, with median TBSA 20 percent in the cohort overall ^[11]. Shirani's landmark 1987 analysis of 1058 admissions documented inhalation injury in 35 percent of patients, with subsequent pneumonia in 38 percent of those affected versus 8.8 percent in patients without inhalation injury ^[14]. A 2025 systematic review and meta-analysis confirmed that approximately one-third of major burns are complicated by burn-related inhalation injury, with more severe bronchoscopic grades carrying significantly higher pneumonia risk (RD 0.32, 95% CI 0.02-0.62) and ARDS risk (RD 0.24, 95% CI 0.12-0.37) ^[12].

The independent mortality contribution of inhalation injury is established. A systematic review of 13 studies reported overall burn mortality of 13.9 percent rising to 27.6 percent in patients with inhalation trauma, with TBSA, presence of inhalation injury, and age as the strongest predictors across the literature ^[18]. Inhalation injury alone increases burn mortality by a maximum of approximately 20 percent, pneumonia adds a maximum of another 40 percent, and the combination drives mortality up by a maximum of 60 percent, with maximum effect in the midrange of expected baseline mortality [14, 1]. In multivariable analysis of the 12-year UK cohort, severe inhalation injury was independently associated with mortality (adjusted HR 2.14, 95% CI 1.12-4.09), alongside facial burns, higher TBSA, and older age ^[11].

Burns and inhalation injury impose substantial healthcare cost, with percent TBSA burn the primary determinant of cost across length of stay, operative care, dressings, and staffing in a single-center analysis ^[19]. Fire-related fatalities are driven heavily by inhalation: in the United States, the majority of fatalities from fire and burns occur because of inhalation of smoke rather than from cutaneous injury ^[16]. In one large fatality series, mean carboxyhemoglobin levels reached 44.9 percent across 433 fire fatalities ^[20]; in a separate three-year Ontario series, the highest carbon monoxide levels were observed in victims discovered in motor vehicles ^[21]. Self-immolation accounts for a small but distinct fraction of fire deaths; in one three-year Ontario series, self-immolation represented about 1 percent of suicides and a significant number died from combined smoke inhalation and carbon monoxide poisoning rather than from the cutaneous burn alone ^[21].

Pathophysiology

Smoke inhalation injury follows four fairly discrete but overlapping phases of pulmonary parenchymal damage, characterized in an ovine model whose pathophysiology has parallels with the human course ^[23].

The microvascular insult is the load-bearing pathophysiologic event. Smoke inhalation triggers a marked, sustained increase in pulmonary microvascular permeability that drives interstitial and alveolar edema, with derived pulmonary capillary pressure and lung lymph flow both rising significantly in ovine models ^[24]. Inducible nitric oxide synthase upregulation in pulmonary tissue contributes to permeability change; specific iNOS inhibition suppresses both the systemic and pulmonary microvascular leak in animal studies ^[25]. Combined burn and smoke inhalation impairs hypoxic pulmonary vasoconstriction by approximately 90 percent in ovine models, producing the characteristic pulmonary shunting and the deceptively preserved early blood gases that mask the magnitude of underlying injury ^[26]. Bronchoalveolar lavage in fire victims demonstrates pulmonary alveolar macrophage activation with significant increases in polymorphonuclear leukocytes and macrophages, especially mature forms, and greater chemiluminescence than controls — evidence that lung damage in combined injury follows from excess inflammatory-mediator release exceeding the lung's reserve capacity ^[22]. Endothelial glycocalyx damage occurs early, with circulating syndecan-1 rising significantly within two to six hours of injury in animal models, providing biomarker evidence that endothelial injury is part of the initiating cascade rather than a downstream consequence ^[28].

Airway obstruction from cast formation is the second key mechanism. Bronchial and bronchiolar casts in combined smoke-and-burn ovine models are composed of mucus at early time points and of neutrophils at later time points, with airway obstruction scores correlating strongly with PaO2/FiO2 ratios (r = 0.76) ^[27]. The mucus-then-neutrophil composition explains why mucolytic and anticoagulant strategies converge on the same airway-clearance target through different mechanisms. Vascular endothelial growth factor expression is upregulated in lung tissue after combined smoke inhalation and pneumonia, paralleling the time course of microvascular hyperpermeability ^[29].

The systemic inflammatory response is graded with injury severity. The acute pulmonary inflammatory response increases stepwise with the bronchoscopic grade of smoke inhalation injury ^[30], and plasma immune mediators including IL-1RA, IL-6, IL-8, and granulocyte colony-stimulating factor rise with worse injury severity even after adjustment for age and TBSA ^[32]. IL-1RA is independently associated with mortality (OR 3.12, 95% CI 1.03-9.44) in inhalation injury and may be the strongest single immune mediator linking pulmonary and systemic outcomes [31, 32]. Pulmonary edema in combined burn-and-smoke injury is driven by augmented microvascular permeability to fluid rather than to protein, and the early cardiovascular dysfunction is dominated by hypovolemia from the cutaneous burn while a later, smoke-attributable myocardial contractile depression appears independent of preload ^[33]. Antithrombin depletion during the systemic septic phase contributes to airway cast formation, and antithrombin supplementation attenuates casting in ovine models ^[34].

Classification

Inhalation injury is classified in two complementary frames: bronchoscopic grade of airway injury at admission, and ARDS classification by Berlin criteria as pulmonary failure develops.

Bronchoscopic grading systems

Multiple grading schemes coexist in the literature. The most widely used is the Abbreviated Injury Score (AIS), a five-level system (grade 0 no injury, grade 1 mild, grade 2 moderate, grade 3 severe, grade 4 massive) that has been validated against early oxygenation indices: ARDS incidence rose stepwise with AIS grade — 0%, 22%, 57%, and 80% at 24 hours in the original validation cohort — and severe inhalation injury (grades 2 and 3) was associated with significantly increased ARDS risk at 24 and 72 hours after adjustment for age, TBSA, and full-thickness burn component ^[6]. Alternative schemes include the Ikonomidis ENT/TB descriptive score, which grades ENT and tracheobronchial lesions on the same 1-to-3 ordinal scale and was developed specifically to provide a unified diagnostic language ^[35]. Other authors have proposed three-degree morphologic systems, with first-, second-, and third-degree injury corresponding to mucosal hyperemia and edema, frank erosion, and necrosis respectively; recovery times in one series averaged 7, 16, and 29 days across these grades ^[36].

ARDS classification

Burn-related ARDS is now classified by the Berlin criteria in most centers. The Berlin definition shows statistically significant mortality stratification across mild, moderate, and severe ARDS categories in burn patients, whereas the older AECC definition did not stratify mortality as cleanly ^[37]. The Berlin criteria's validity in burn-induced ARDS has been questioned: in one 2024 single-center cohort, mortality was under 10 percent in the early-ARDS group regardless of PF ratios, and patients with concurrent inhalation injury showed significantly lower PF ratios and higher SOFA scores without a corresponding mortality penalty, suggesting the Berlin criteria's mortality-tracking assumption may not hold in burn-induced ARDS ^[38]. The implication is that PF ratio at presentation in the burn patient may reflect mechanism (capillary leak, cast formation, shunt) more than prognosis.

Limitations of current classification

Inter-rater reliability for bronchoscopic grading is a substantial limitation. The 2025 iBRONCH-BII study reported kappa of 0.30 for inter-rater agreement across 17 specialist clinicians and 10 novices grading 16 bronchoscopic images — a level of agreement clinically inadequate to support cross-center comparisons or trial enrollment ^[39]. A 2026 deep-learning vision-transformer framework trained on patient bronchoscopy recordings achieved 98 percent accuracy on internal test sets and demonstrated the technical feasibility of automated AIS grading, though external validation and prospective deployment remain to be established ^[40].

Assessment

Bronchoscopic diagnosis

Fiberoptic bronchoscopy is the diagnostic gold standard for inhalation injury, originally established as a simple, safe, and accurate diagnostic method that identifies both the anatomic level and the severity of large-airway injury ^[5]. Both supraglottic and infraglottic components can be identified, with implications for both therapy and prognosis ^[5]. The one clinical situation in which bronchoscopy reliably fails to detect inhalation injury is the immediate postburn period before hypovolemic shock has been corrected; after volume restoration, characteristic mucosal changes appear ^[5]. Xenon-133 ventilation-perfusion lung scans are an older complementary modality that historically detected small-airway involvement before chest radiograph abnormalities became visible ^[41]. An inhalation injury scoring system based on history, physical examination, bronchoscopic findings, and xenon lung-scan abnormalities correlated well with postinjury changes in compliance and subsequent sequelae ^[42]. Zawacki's six-factor probit model identified age, total burn area, third-degree burn area, prior bronchopulmonary disease, abnormal PaO2, and airway edema as the on-admission factors that best discriminated survivors from non-survivors — a model that anchors the historical understanding that inhalation injury sits alongside age and TBSA as a primary determinant of outcome ^[43].

Intubation decision

When and whom to intubate is the most contested bedside decision in inhalation injury. Recent studies demonstrate that burn patients are routinely undergoing unnecessary intubations: in one cohort of 218 patients with thermal burns, 67 of 218 (31 percent) had short-term intubation (under 48 hours), and the long-term intubation group was more strongly associated with ABA criteria than with traditional criteria ^[44]. The Denver criteria, derived from this analysis, enumerate ten findings for intubation consideration: full-thickness facial burns, stridor, respiratory distress, swelling on laryngoscopy, upper airway trauma, altered mentation, hypoxia or hypercarbia, hemodynamic instability, suspected smoke inhalation, and singed facial hair; these criteria increased sensitivity for long-term intubation to 95 percent at the cost of specificity (24 percent) ^[44]. A separate prospective evaluation of nasolaryngoscopy in initial burn-patient assessment found that none of 130 asymptomatic patients with negative nasolaryngoscopy were intubated, and asymptomatic patients showed pathologic changes on scope in 30 percent of cases that altered management only 1 percent of the time, supporting a thorough history and physical as the best screening tool with nasolaryngoscopy reserved for symptomatic patients ^[45]. Comparing liberal versus restrictive intubation criteria in a single-center cohort, liberal criteria had higher sensitivity (0.98 vs 0.84) for prolonged intubation but markedly lower specificity (0.48 vs 0.96), with 90 percent of patients meeting liberal but not restrictive criteria not having inhalation injury and most extubated within 48 hours ^[46]. Provider type matters less than criteria: in a 388-patient analysis, surgical providers with ACS backgrounds and Advanced Trauma Life Support training showed no difference from burn providers in emergent intubation rates, time to extubation, or diagnostic accuracy ^[47].

Role of repeat bronchoscopy

Repeat bronchoscopies have been the subject of skepticism. A 2025 analysis of 99 patients found that after adjustment for age, TBSA, and injury severity, no individual day of repeat bronchoscopy was significant for predicting outcomes, with AUCs uniformly below 0.8 ^[48]. The findings do not support repeat bronchoscopies for prognostication; the authors suggest that until a larger randomized clinical trial evaluates them, serial bronchoscopies for assessing progression of inhalation injury may provide more risk than benefit ^[48].

Predictors of fluid requirement

P/F ratio at presentation predicts increased fluid requirement during acute resuscitation more reliably than bronchoscopic grade. Patients with admission P/F ratio below 350 received significantly more mL/kg/%TBSA during acute resuscitation than those with P/F above 350, whereas bronchoscopic grades 2-4 did not have increased acute fluid requirements compared with grades 1 and 2 injuries ^[49]. Bronchoscopic grade remains the better predictor of overall mortality, while P/F ratio is the better intra-resuscitation guide ^[49].

Toxin exposure

Carboxyhemoglobin is the only on-admission biomarker of inhalation exposure with established prognostic and therapeutic implications. Cyanide poisoning is infrequent in fire fatalities but is associated with significant concurrent carboxyhemoglobinemia (mean COHb 62.5 percent in fatalities with cyanide above 3 mg/L), and blood cyanide levels are difficult to interpret ^[20]. Hydroxocobalamin administration has not been associated with clinically significant methemoglobinemia in matched-cohort analysis of burn patients receiving the drug for suspected cyanide toxicity ^[50].

Management

The management of inhalation injury is supportive, organized around the supportive-care pillars of airway protection, lung-protective ventilation, airway clearance, gas-exchange support, and selective treatment of systemic toxins [1, 4].

Airway management

Early intubation, preferably with a fiberoptic bronchoscope, is favored before airway edema renders intubation technically difficult ^[3]. For initial respiratory support, translaryngeal (nasotracheal) tubes for periods up to 3 weeks are the historic preference ^[42]. The intubation criteria above (Assessment) drive selection; the over-intubation problem is now widely recognized and the Denver-type criteria represent an attempt to reduce it [44, 46]. Fluid resuscitation in modern burn cohorts has often exceeded Parkland prediction (mean 6.7 mL/kg/%TBSA in one inhalation-injury-excluded burn cohort, with 84 percent of patients exceeding formula estimates), although whether the Parkland under-prediction generalizes to inhalation-injury subpopulations and modern protocol-driven centers is unsettled ^[51]. Avoidance of hyperoxia during initial resuscitation is increasingly emphasized: in a 219-patient retrospective analysis, early hyperoxia was common and possibly associated with increased overall mortality in unadjusted analysis, but after adjusting for burn-specific scoring systems the authors found a negative correlation between hyperoxia and mortality, leaving results inconclusive ^[52].

Cyanide treatment

Hydroxocobalamin is widely used as an empiric antidote in closed-space-fire victims with depressed mental status, persistent acidosis, or hemodynamic instability ^[9]. In Borron's prospective observational case series of 69 patients treated at the fire scene or in the ICU, 72 percent survived after hydroxocobalamin administration, and 67 percent of patients with cyanide poisoning confirmed a posteriori survived; the most common adverse events were chromaturia, pink or red skin discoloration, and transient hypertension, with no serious adverse events attributed to the drug ^[9]. In a more recent 46-patient evaluation using predefined appropriate-use criteria (respiratory arrest, elevated lactate, hypotension, or cardiac arrest), 76 percent met the criteria, with in-hospital mortality of 49 percent in patients meeting criteria versus 9 percent in those who did not, suggesting the criteria successfully identify the most severely ill smoke inhalation victims rather than driving outcome themselves ^[10]. Hydroxocobalamin is not associated with methemoglobinemia in matched cohort analysis ^[50]. Use of hydroxocobalamin in patients with known or suspected cyanide poisoning from closed-space fires has been associated with decreased per-patient hospital costs ($15,381 versus $22,607 in one cost-impact analysis), largely driven by shorter ICU stay ^[53].

Airway clearance pharmacotherapy

Nebulized therapy targets the cast-formation mechanism that obstructs distal airways. Ovine studies established that nebulized epinephrine limits pulmonary vascular hyperpermeability to water and protein in burn and smoke inhalation, providing the preclinical basis for inhaled vasoactive therapy ^[54]. Muscarinic receptor antagonist (tiotropium) attenuates the increases in ventilatory pressures, pulmonary dysfunction, and upper airway obstruction after combined burn and smoke inhalation in sheep ^[55].

In adults, the most evidence-supported clinical protocol is nebulized unfractionated heparin combined with N-acetylcysteine and a bronchodilator. In a 30-patient single-center retrospective study with historical control of mechanically ventilated adult smoke-inhalation patients, the heparin-NAC-albuterol group showed significantly improved Lung Injury Score, respiratory resistance and compliance, and hypoxia scores, with a significant survival benefit most pronounced in patients with APACHE-III scores above 35 (survival 94% vs 57%) ^[56]. A multicenter retrospective evaluation of 35 matched patient trios found that nebulized heparin (5,000 or 10,000 units) was associated with 8 to 11 fewer ventilator days compared with controls, with no major bleeding events ^[57]. A 2020 systematic review and meta-analysis of nine trials reported that nebulized heparin reduced mortality (RR 0.75), shortened mechanical ventilation duration (SMD -0.78), and shortened hospital length of stay (SMD -0.42), without increasing pneumonia or unplanned reintubation rates ^[7]. A 2023 meta-analysis of animal studies confirmed lower mortality (RR 0.42), improved PaO2/FiO2, and reduced lung edema with nebulized heparin in smoke inhalation ^[58]. A 2025 randomized controlled trial of 88 adults randomized to 5,000 IU of nebulized heparin every 4 hours versus placebo found that the heparin arm had significantly more ventilator-free days, higher PaO2/FiO2 ratios, more ICU-free days, and fewer mechanical-ventilation days in survivors; mortality did not differ between arms ^[8]. Heparin alone (without lisofylline) did not attenuate pulmonary dysfunction in an earlier ovine model, supporting the combination approach used clinically ^[59].

Ventilation strategy

High-frequency percussive ventilation (HFPV) has been the dominant alternative to conventional mechanical ventilation in inhalation injury since Cioffi's prospective trial reported reduced pneumonia incidence (25.9% vs historic 45.8%) and reduced mortality (10/54 = 18.5% observed vs expected historic 23/54 deaths, 95% CL 17 to 28) using prophylactic HFPV initiated within 24 hours of intubation ^[60]. Pediatric HFPV showed no cases of pneumonia, better PaO2/FiO2 ratios, lower peak inspiratory pressures, and reduced work of breathing compared to historical controls ^[61]. A subsequent randomized study comparing HFPV with conventional ventilation in 35 adults reported significantly higher PaO2/FiO2 in the HFPV group from days 0 to 3 without differences in other parameters ^[62]. The 2018 systematic review of seven HFPV studies identified mortality and pneumonia improvements in three studies and unchanged rates in three others, with no change in ventilator days or ICU length of stay; oxygenation and work of breathing improved with HFPV, but the absence of high-quality evidence precluded meta-analysis and yielded only a very weak recommendation for HFPV's association with lower mortality in smoke inhalation-associated acute lung injury ^[63]. The literature lacks examination of HFPV's practical application toward improving gas exchange or preventing ventilator-induced lung injury ^[64].

Conventional ventilator practice in burn patients has shifted toward lung-protective settings consistent with non-burn ARDS practice. A 2020 systematic review of 35 ventilator studies in burn patients showed tidal volume declined from 14 mL/kg before 2006 to approximately 8 mL/kg predicted body weight after 2006, with 75 percent of recent studies using maximum airway pressures ≤35 cm H2O; barotrauma was more frequent in patients ventilated with higher airway pressures ^[65]. High-flow nasal oxygen therapy has been described as an alternative in case-series experience with burn-related ARDS ^[66]. Extracorporeal membrane oxygenation has emerged as rescue therapy for refractory hypoxemic respiratory failure: a five-patient series reported successful weaning in all five patients (one later died of multi-organ failure), with mean pre-ECMO ventilation time 7.4 days and mean ECMO duration 18 days ^[67]. A 2023 systematic review and meta-analysis of 15 retrospective ECMO studies (318 patients) reported pooled in-hospital mortality of 49 percent (55% in adults, 35% in pediatrics), with severe ARDS as the most common indication, veno-venous as the most common mode, and infection and bleeding as the most common complications ^[68]. Mortality increased significantly with concurrent inhalation injury and decreased with longer ECMO duration in subgroup analysis, suggesting ECMO is most effective when sustained rather than briefly trialed ^[68]. Multidisciplinary burn-team management of ECMO in severe inhalation injury has been described in single-case detail ^[69]. ECMO without systemic anticoagulation has been used to facilitate surgical repair of delayed tracheoesophageal fistula caused by inhalation burn ^[70].

Tracheostomy

Tracheostomy in severe burns has not shown a clear mortality benefit. In a Japanese nationwide observational study of 680 patients (94 tracheostomy, 586 non-tracheostomy), the adjusted hazard ratio for 28-day mortality with tracheostomy was 0.73 (95% CI 0.39-1.34), and there was no significant association between early tracheostomy and 28-day in-hospital mortality ^[71]. Upper airway sequelae remain a concern: tracheal stenosis and tracheal scar granuloma formation are more frequent and more severe after tracheostomy than after translaryngeal intubation, and duration of tube placement and presence of a tracheal stoma are independent predictors of these complications ^[42].

Bronchial hygiene and rehabilitation

Chest physical therapy reduces pneumonia incidence following inhalation injury. In a 139-patient analysis, the CPT group had a hazard ratio for first pneumonia of 0.27 (95% CI 0.13-0.54) versus conventional therapy after propensity-score adjustment, and patients required fewer days until they could sit at the bed edge ^[72]. Bronchial hygiene comprising therapeutic coughing, chest physiotherapy, deep breathing exercises, and early ambulation is standard in protocol-driven respiratory care ^[3].

Therapies not recommended

Prophylactic systemic antibiotics and prophylactic systemic corticosteroids are not supported by the available evidence and are not recommended in inhalation injury ^[4]. The historic dexamethasone-and-gentamicin trial in inhalation injury showed no differences in mortality, pulmonary complications, or pulmonary function with either drug ^[89].

Complications

The dominant complications cluster around pneumonia, ARDS, abdominal compartment syndrome from over-resuscitation, and late upper-airway sequelae such as tracheal stenosis.

Pneumonia

Pneumonia is the most consequential pulmonary complication. Pneumonia occurs in 38 percent of patients with inhalation injury versus 8.8 percent in those without, and the combination of inhalation injury and pneumonia increases mortality by 60 percent versus inhalation injury alone (20 percent increase) or pneumonia alone (40 percent increase) ^[14]. In the 12-year UK cohort, pneumonia carried higher mortality (27% vs 11%) but in multivariable analysis pneumonia did not independently increase mortality from inhalation injury ^[11]. In a 2023 analysis of pneumonia in inhalation injury, pneumonia patients spent more time on the ventilator, had longer hospitalizations, and were more likely to need tracheostomy; pneumonia was independently associated with total ventilator days (OR 1.12 per day) but was not an independent predictor of length of stay, ARDS, or mortality after multivariable adjustment ^[13]. Pneumonia and receipt of colloid during the first 24 hours were both predictive of increased ventilator days ^[13]. Vancomycin dosing in burn patients with thermal or inhalation injury showed no difference in clinical success between AUC and trough-based monitoring strategies in a 485-patient multicenter analysis ^[74].

Abdominal compartment syndrome

Abdominal compartment syndrome is frequently the result of aggressive fluid resuscitation after burn ^[73]. The Wittmann Patch has been described as a temporary abdominal closure device after decompressive celiotomy, with all survivors undergoing primary abdominal closure without ventral hernia at follow-up ^[73]. Increased fluid volume received increases the risk of pneumonia (OR 1.92), bloodstream infection (OR 2.33), ARDS (OR 1.55), and multi-organ failure independently, establishing fluid administration as a modifiable risk factor that compounds inhalation injury rather than rescuing it ^[17].

Coagulopathy

Disorders of the coagulation pathway are triggered early in patients with severe burn and inhalation injuries. In a 433-patient cohort, activated partial thromboplastin time was a risk factor for death, anticoagulation, and continuous renal replacement therapy outcomes; D-dimer was a risk factor for death and high-risk coagulopathy was an independent risk factor for death ^[75]. Age, TBSA, lactate level, and prehospital infusion volume were independent influencing factors on high-risk coagulopathy ^[75].

Late upper-airway sequelae

Dysphonia is a frequent late complication. In a 167-patient 10-year review, dysphonia was observed in 55 percent overall and rose to 87 percent in those with severe inhalation injury ^[84]. By 6 months, dysphonia had resolved in 98 percent of the non-severe and 73 percent of the severe cohort, leaving a substantial minority of severe-injury patients with persistent dysphonia at six months ^[84]. Laryngeal pathology in this series included edema/erythema, laryngeal granulation, vocal cord palsy or paresis, and laryngeal contracture ^[84]. Most patients with abnormal laryngeal findings remain dysphonic decades after the initial injury ^[76]. The degree of subglottic damage is more extensive and occurs sooner in patients with inhalation injury than in those without ^[76]. Long-term outpatient pulmonary sequelae are significantly higher for inhalation-injury and ventilated patients than for non-ventilated burn patients, and inhalation-injury patients present with complaints earlier than ventilated patients (mean 162 days from discharge versus 513 days) ^[83].

Ventilator-associated complications

Barotrauma in the burn ventilator literature ranges from 0 to 29 percent across studies, and is more frequent in patients ventilated with higher airway pressures ^[65].

Special Considerations

Pediatric patients

Pediatric inhalation injury management mirrors adult practice with one published pediatric-specific observation: HFPV in a pediatric series showed no pneumonia, better PaO2/FiO2 ratios, lower peak inspiratory pressures, and reduced work of breathing versus historical controls ^[61].

Elderly patients

In a Northern Ireland series, smoke inhalation was diagnosed in 10 patients and the cohort experienced 18 deaths versus an expected 33, attributing relative survival improvement to modern critical care; however, the elderly burn population has cardiovascular disease as the predominant pre-morbid condition driving outcomes ^[77].

E-cigarette explosion injuries

Jones et al. propose that e-cigarette explosion injuries be reviewed with a high index of clinical suspicion for inhalation injury alongside facial trauma in burn admissions presenting with characteristic facial-burn patterns near vape device proximity ^[78].

Hydrofluoric acid

Hydrofluoric acid is unique in both the severity of cutaneous burns it produces and its potential for systemic and occasionally lethal toxicity; Kirkpatrick et al. characterize the literature on HF injury management as extensive but inconsistent and note that no coherent management policy has emerged ^[79]. HF injury with an inhalation component is conventionally managed with hypocalcemia surveillance and specialized referral at centers experienced with the agent.

Pre-existing pulmonary disease

COPD does not independently worsen short-term outcomes following fire-related inhalation injuries in one 184-patient analysis: COPD did not predict differences in hospital days, ventilator days, complication rates, or mortality (OR 0.61, 95% CI 0.24-1.53), although patients who died with COPD survived 6 days longer ^[87]. Carbon monoxide poisoning was the predominant mortality risk factor in that cohort (OR 3.80) ^[87].

Outcomes

Mortality in inhalation injury is driven primarily by burn size, age, and the presence and severity of pulmonary injury. The classical three-factor model — age, percent TBSA burned, and presence of inhalation injury — remains the framework most prognostic scoring systems use, with relative weighting varying between systems ^[82]. Inhalation injury alone increases burn mortality by approximately 20 percent, and the combination of inhalation injury and pneumonia increases mortality by 60 percent ^[14]. In a Saudi Arabian critical-care cohort, inhalational injuries were reported in 18 patients of whom 13 (72 percent) died, and patients with patent airway and no inhalation injury were 19 times more likely to survive than those with compromised airway ^[80]. In a comprehensive retrospective analysis of 396 burn patients, the best multivariable mortality model included heart failure, acute kidney injury, admission Glasgow Coma Scale score, and revised Baux score; for patients over 60, the best on-admission model included heart failure, percent TBSA burned, and inhalation injury ^[81]. The Inhalation Injury Severity Score (I-ISS) predicted overall survival in burn patients independently of other scoring systems (OR 13.16 for score 3 versus scores 1-2) ^[99]. Machine-learning models for inhalation-injury severity prediction have reported AUCs around 0.86 to 0.88 in proof-of-concept work ^[97].

ARDS develops in roughly half of intubated burn patients (53.6% by American-European Consensus and 45.2% by Lung Injury Severity Score in one 469-patient cohort), with delayed onset (mean 6.9-8.2 days from admission) compared with most critical-care populations; age is the major predisposing factor in burn ARDS, with inhalation injury showing a trend toward increased ARDS but not reaching statistical significance after multivariable adjustment in some series ^[100]. Restrictive fluid balance in the resorption stage correlates with better outcomes: in severe burn patients, the daily net fluid balance of deceased patients was higher than that of survivors on days 4-7 post-injury, and greater fluid output in the resorption stage was closely related to better outcomes ^[101].

Long-term sequelae extend years beyond the acute hospitalization. Inhalation-injury and ventilated burn patients carry significantly higher rates of outpatient pulmonary sequelae independent of inpatient course compared with non-ventilated patients ^[83]. Persistent dysphonia at six months affects 27 percent of severe inhalation-injury patients ^[84]. Implementation of a structured burn protocol in one 20-year experience was associated with substantial reductions in all-cause mortality (8.1% versus 47.6%) and renal replacement therapy, suggesting that organized, protocol-driven care delivers meaningful outcome improvements beyond what is attributable to any single therapy ^[88].

Controversies and Evidence Gaps

The literature on inhalation injury and pulmonary management has several active controversies, each with substantive bedside implications.

Bronchoscopic grading reliability and prognostic value

The 2025 iBRONCH-BII study reported inter-rater reliability of k = 0.30 for the AIS in bronchoscopic grading of burn inhalation injury, a level clinically inadequate to support cross-center comparison or trial enrollment ^[39]. Mortality association with severe bronchoscopic injury was statistically insufficient (RD 0.07, p = 0.116) in the 2025 systematic review, even where pneumonia and ARDS associations reached significance ^[12]. Strategies to improve grading reliability are required, and standardization of bronchoscopic classification with integration of objective clinical parameters is an open research priority [12, 39]. Whether deep-learning automated grading will resolve the reliability problem at scale remains to be tested in prospective deployment ^[40].

Repeat bronchoscopy utility

A 2025 analysis of 99 patients found that no individual day of repeat bronchoscopy predicted outcomes (AUCs uniformly under 0.8); the authors concluded that serial bronchoscopies may carry more risk than benefit pending a randomized trial ^[48]. Centers that perform daily bronchoscopy through the first week as a matter of protocol should weigh this signal against their local convention.

Optimal ventilation strategy

The HFPV-versus-conventional-mechanical-ventilation question remains unsettled. The 2018 systematic review identified mortality and pneumonia improvements with HFPV in three studies and unchanged rates in three others, with only very weak recommendation strength supportable from low-quality evidence ^[63]. The 2020 ventilator-trends review noted that burn-patient ventilator practice now mirrors non-burn-critical-care practice (low tidal volume, limited airway pressure) without firm data on the burn-specific consequences of that convergence ^[65]. Randomized trials of HFPV versus conventional lung-protective ventilation in the inhalation injury population have not been conducted, leaving clinicians without high-quality comparative effectiveness data.

Pharmacotherapy gaps

The American Burn Association working group on Cutaneous Thermal Injury identified persistent gaps in airway repair mechanisms, airway microbiome characterization, and candidate biomarkers of inhalation injury, alongside lack of universal recommendations for mucolytics, anticoagulants, bronchodilators, and modified ventilator strategies ^[86]. The pharmacotherapy-pertinent literature of 2021-2022 yielded 98 manuscripts of potential interest from 2,336 screened, with only 17 percent assessed as likely to have little effect on current practice — suggesting active iteration in burn-pharmacology evidence without convergence on a unified standard ^[102]. The 2018 evidence-based review of inhalation injury management identified bronchoscopy, permissive hypercapnia, and a small set of additional strategies as supported by the literature, while flagging high-frequency oscillatory ventilation and exogenous surfactant as not harmful but not firmly established ^[4]. The general state of inhalation injury evidence is Level 3 or below, with a notable lack of large-scale human studies ^[4].

Carbon monoxide management

Hyperbaric oxygen treatment for carbon monoxide exposure has been evaluated in multiple trials, but available data do not support application of hyperbaric oxygen outside the context of clinical trials ^[85]. Indications and dosing for HBO in burn-associated CO toxicity remain a center-specific judgment without uniform guideline support.

Cyanide management consistency

Specific antidote therapy for cyanide toxicity is supported by European data but consistent international support is lacking ^[85]. Hydroxocobalamin is used empirically prior to laboratory confirmation in fire victims, and predefined appropriate-use criteria such as respiratory arrest, elevated lactate, hypotension, or cardiac arrest identify severely ill patients eligible for empiric treatment [9, 10]; precise appropriate-use criteria continue to evolve and centers vary in their threshold for empiric treatment.

Berlin criteria validity in burn-induced ARDS

A 2024 single-center cohort raised the concern that the Berlin criteria's mortality-tracking assumption may not hold in burn-induced ARDS: the early ARDS group had under 10 percent mortality regardless of PF ratios, and concurrent inhalation injury produced lower PF ratios without a corresponding mortality penalty ^[38]. Whether burn ARDS warrants a modified classification framework remains an open question for the field.

Translation of preclinical interventions

A long list of pharmacologic interventions has been validated in ovine combined-burn-and-smoke models — iNOS inhibition ^[25], nNOS inhibition ^[93], arginine vasopressin ^[94], bronchial-artery sclerosis ^[95], L-selectin antibody ^[96], poly(ADP-ribose) synthetase inhibition ^[98], antithrombin supplementation ^[34] — but none has progressed to human clinical adoption. The translational gap between ovine preclinical data and human trials is the dominant feature of the modern inhalation-injury research landscape and reflects both the difficulty of mounting adequately powered clinical trials in this population and the heterogeneity of human inhalation exposure compared with the standardized ovine model [2, 86].

Bedside knowledge and protocol adherence

Implementation of structured burn-nursing handbooks improved fundamental burn-knowledge survey scores from 55.9 percent to 69.6 percent in one quality-improvement evaluation, illustrating that gaps in bedside knowledge are addressable but persistent in routine burn nursing practice ^[103]. Procalcitonin and IL-6 were identified as prognostic markers of mortality at admission but were less reliable than the clinical unit-burn-standard score, and ProCT was not associated with smoke inhalation specifically ^[104]. Pneumonia in 9 of 60 (15 percent) inhalation patients in one cohort developed despite intensive bronchoscopic surveillance, indicating that grading alone does not capture the eventual infection trajectory ^[36]. Early-injury gene-expression analyses comparing burn-only with burn-plus-inhalation patients showed no significant differences in immune regulation or cell adjustment pathways at the early time points sampled, suggesting that the systemic inflammatory response is not divergent between injury types within the first hours despite the divergent long-term trajectories ^[91]. Respiratory function testing in burn survivors with inhalation injury shows a mild restrictive pattern with reduced diffusing capacity and expiratory muscle weakness, providing the substrate for the rehabilitation-phase clinical work ^[92].

References

[1] Mlcak RP, Suman OE, Herndon DN. "Respiratory management of inhalation injury." Burns : journal of the International Society for Burn Injuries 2007. PMID: 17223484. https://pubmed.ncbi.nlm.nih.gov/17223484/

[2] Enkhbaatar P, Pruitt BA, Suman O, Mlcak R, Wolf SE, Sakurai H, et al. "Pathophysiology, research challenges, and clinical management of smoke inhalation injury." Lancet (London, England) 2016. PMID: 27707500. https://pubmed.ncbi.nlm.nih.gov/27707500/

[3] Gupta K, Mehrotra M, Kumar P, Gogia AR, Prasad A, Fisher JA. "Smoke Inhalation Injury: Etiopathogenesis, Diagnosis, and Management." Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 2018. PMID: 29657376. https://pubmed.ncbi.nlm.nih.gov/29657376/

[4] Deutsch CJ, Tan A, Smailes S, Dziewulski P. "The diagnosis and management of inhalation injury: An evidence based approach." Burns : journal of the International Society for Burn Injuries 2018. PMID: 29398078. https://pubmed.ncbi.nlm.nih.gov/29398078/

[5] Hunt JL, Agee RN, Pruitt BA. "Fiberoptic bronchoscopy in acute inhalation injury." The Journal of trauma 1975. PMID: 1152086. https://pubmed.ncbi.nlm.nih.gov/1152086/

[6] Mosier MJ, Pham TN, Park DR, Simmons J, Klein MB, Gibran NS. "Predictive value of bronchoscopy in assessing the severity of inhalation injury." Journal of burn care & research : official publication of the American Burn Association 2012. PMID: 21941194. https://pubmed.ncbi.nlm.nih.gov/21941194/

[7] Lan X, Huang Z, Tan Z, Huang Z, Wang D, Huang Y. "Nebulized heparin for inhalation injury in burn patients: a systematic review and meta-analysis." Burns & trauma 2020. PMID: 32523966. https://pubmed.ncbi.nlm.nih.gov/32523966/

[8] Hakim SM, Fouad MN, Habib MK, Mohamed MS, Ghaly SI. "Effect of early administration of inhaled heparin on outcomes of smoke inhalation injury: A randomized controlled trial." Burns : journal of the International Society for Burn Injuries 2025. PMID: 40319829. https://pubmed.ncbi.nlm.nih.gov/40319829/

[9] Borron SW, Baud FJ, Barriot P, Imbert M, Bismuth C. "Prospective study of hydroxocobalamin for acute cyanide poisoning in smoke inhalation." Annals of emergency medicine 2007. PMID: 17481777. https://pubmed.ncbi.nlm.nih.gov/17481777/

[10] Kamta J, Maynard K, Schult RF, Bell DE, Jones CMC, Acquisto NM. "Evaluation of hydroxocobalamin use for the treatment of suspected cyanide toxicity secondary to smoke inhalation." Burns : journal of the International Society for Burn Injuries 2024. PMID: 37777459. https://pubmed.ncbi.nlm.nih.gov/37777459/

[11] Charles WN, Collins D, Mandalia S, Matwala K, Dutt A, Tatlock J, et al. "Impact of inhalation injury on outcomes in critically ill burns patients: 12-year experience at a regional burns centre." Burns : journal of the International Society for Burn Injuries 2022. PMID: 34924231. https://pubmed.ncbi.nlm.nih.gov/34924231/

[12] Amarasekera NN, Jha A, Charles WN, Dutt A, Milton-Jones H, Kumana E, et al. "Evaluating the association between bronchoscopic severity of burns-related smoke inhalation injury and clinical outcomes: A systematic review and meta-analysis." Burns : journal of the International Society for Burn Injuries 2025. PMID: 41101183. https://pubmed.ncbi.nlm.nih.gov/41101183/

[13] Ronkar NC, Galet C, Richey K, Foster K, Wibbenmeyer L. "Predictors and Impact of Pneumonia on Adverse Outcomes in Inhalation Injury Patients." Journal of burn care & research : official publication of the American Burn Association 2023. PMID: 37352120. https://pubmed.ncbi.nlm.nih.gov/37352120/

[14] Shirani KZ, Pruitt BA, Mason AD. "The influence of inhalation injury and pneumonia on burn mortality." Annals of surgery 1987. PMID: 3800465. https://pubmed.ncbi.nlm.nih.gov/3800465/

[15] Enkhbaatar P, Traber DL. "Pathophysiology of acute lung injury in combined burn and smoke inhalation injury." Clinical science (London, England : 1979) 2004. PMID: 15151496. https://pubmed.ncbi.nlm.nih.gov/15151496/

[16] Peck MD. "Structure fires, smoke production, and smoke alarms." Journal of burn care & research : official publication of the American Burn Association 2011. PMID: 21785363. https://pubmed.ncbi.nlm.nih.gov/21785363/

[17] Klein MB, Hayden D, Elson C, Nathens AB, Gamelli RL, Gibran NS, et al. "The association between fluid administration and outcome following major burn: a multicenter study." Annals of surgery 2007. PMID: 17414612. https://pubmed.ncbi.nlm.nih.gov/17414612/

[18] Colohan SM. "Predicting prognosis in thermal burns with associated inhalational injury: a systematic review of prognostic factors in adult burn victims." Journal of burn care & research : official publication of the American Burn Association 2010. PMID: 20523229. https://pubmed.ncbi.nlm.nih.gov/20523229/

[19] Ahn CS, Maitz PK. "The true cost of burn." Burns : journal of the International Society for Burn Injuries 2012. PMID: 22795515. https://pubmed.ncbi.nlm.nih.gov/22795515/

[20] Barillo DJ, Goode R, Esch V. "Cyanide poisoning in victims of fire: analysis of 364 cases and review of the literature." The Journal of burn care & rehabilitation 1994. PMID: 8150843. https://pubmed.ncbi.nlm.nih.gov/8150843/

[21] Shkrum MJ, Johnston KA. "Fire and suicide: a three-year study of self-immolation deaths." Journal of forensic sciences 1992. PMID: 1545201. https://pubmed.ncbi.nlm.nih.gov/1545201/

[22] Clark CJ, Pollock AJ, Reid WH, Campbell D, Gemmell C. "Role of pulmonary alveolar macrophage activation in acute lung injury after burns and smoke inhalation." Lancet (London, England) 1988. PMID: 2902318. https://pubmed.ncbi.nlm.nih.gov/2902318/

[23] Linares HA, Herndon DN, Traber DL. "Sequence of morphologic events in experimental smoke inhalation." The Journal of burn care & rehabilitation 1989. PMID: 2921256. https://pubmed.ncbi.nlm.nih.gov/2921256/

[24] Isago T, Fujioka K, Traber LD, Herndon DN, Traber DL. "Derived pulmonary capillary pressure changes after smoke inhalation in sheep." Critical care medicine 1991. PMID: 1935162. https://pubmed.ncbi.nlm.nih.gov/1935162/

[25] Soejima K, Traber LD, Schmalstieg FC, Hawkins H, Jodoin JM, Szabo C, et al. "Role of nitric oxide in vascular permeability after combined burns and smoke inhalation injury." American journal of respiratory and critical care medicine 2001. PMID: 11254534. https://pubmed.ncbi.nlm.nih.gov/11254534/

[26] Westphal M, Cox RA, Traber LD, Morita N, Enkhbaatar P, Schmalstieg FC, et al. "Combined burn and smoke inhalation injury impairs ovine hypoxic pulmonary vasoconstriction." Critical care medicine 2006. PMID: 16540966. https://pubmed.ncbi.nlm.nih.gov/16540966/

[27] Cox RA, Burke AS, Soejima K, Murakami K, Katahira J, Traber LD, et al. "Airway obstruction in sheep with burn and smoke inhalation injuries." American journal of respiratory cell and molecular biology 2003. PMID: 12936906. https://pubmed.ncbi.nlm.nih.gov/12936906/

[28] Kelly EJ, Carney BC, Oliver MA, Keyloun JW, Prindeze NJ, Nisar S, et al. "Endothelial damage occurs early after inhalation injury as measured by increased syndecan-1 levels." Journal of burn care & research : official publication of the American Burn Association 2023. PMID: 36928710. https://pubmed.ncbi.nlm.nih.gov/36928710/

[29] Lange M, Hamahata A, Traber DL, Connelly R, Nakano Y, Traber LD, et al. "Pulmonary microvascular hyperpermeability and expression of vascular endothelial growth factor in smoke inhalation- and pneumonia-induced acute lung injury." Burns : journal of the International Society for Burn Injuries 2012. PMID: 22647495. https://pubmed.ncbi.nlm.nih.gov/22647495/

[30] Albright JM, Davis CS, Bird MD, Ramirez L, Kim H, Burnham EL, et al. "The acute pulmonary inflammatory response to the graded severity of smoke inhalation injury." Critical care medicine 2012. PMID: 22067627. https://pubmed.ncbi.nlm.nih.gov/22067627/

[31] Mandrup-Poulsen T, Wogensen LD, Jensen M, Svensson P, Nilsson P, Emdal T, et al. "Circulating interleukin-1 receptor antagonist concentrations are increased in adult patients with thermal injury." Critical care medicine 1995. PMID: 8001382. https://pubmed.ncbi.nlm.nih.gov/8001382/

[32] Davis CS, Janus SE, Mosier MJ, Carter SR, Gibbs JT, Ramirez L, et al. "Inhalation injury severity and systemic immune perturbations in burned adults." Annals of surgery 2013. PMID: 23160150. https://pubmed.ncbi.nlm.nih.gov/23160150/

[33] Soejima K, Schmalstieg FC, Sakurai H, Traber LD, Traber DL. "Pathophysiological analysis of combined burn and smoke inhalation injuries in sheep." American journal of physiology. Lung cellular and molecular physiology 2001. PMID: 11350803. https://pubmed.ncbi.nlm.nih.gov/11350803/

[34] Murakami K, McGuire R, Cox RA, Jodoin JM, Schmalstieg FC, Traber LD, et al. "Recombinant antithrombin attenuates pulmonary inflammation following smoke inhalation and pneumonia in sheep." Critical care medicine 2003. PMID: 12576969. https://pubmed.ncbi.nlm.nih.gov/12576969/

[35] Ikonomidis C, Lang F, Radu A, Berger MM. "Standardizing the diagnosis of inhalation injury using a descriptive score based on mucosal injury criteria." Burns : journal of the International Society for Burn Injuries 2012. PMID: 22348802. https://pubmed.ncbi.nlm.nih.gov/22348802/

[36] Ligen L, Hongming Y, Feng L, Chuanan S, Daifeng H, Xiaoye T. "Morphologic changes and prognosis of the respiratory tract epithelium in inhalation injury and their relationship with clinical manifestations." Surgery 2012. PMID: 21899868. https://pubmed.ncbi.nlm.nih.gov/21899868/

[37] Bordes J, Lacroix G, Esnault P, Goutorbe P, Cotte J, Dantzer E, et al. "Comparison of the Berlin definition with the American European consensus definition for acute respiratory distress syndrome in burn patients." Burns : journal of the International Society for Burn Injuries 2014. PMID: 24685349. https://pubmed.ncbi.nlm.nih.gov/24685349/

[38] Sjoberg F, Elmasry M, Abdelrahman I, Nyberg G, T-Elserafi A, Ursing E, et al. "The impact and validity of the Berlin criteria on burn-induced ARDS: Examining mortality rates, and inhalation injury influences. A single center observational cohort study." Burns : journal of the International Society for Burn Injuries 2024. PMID: 38777667. https://pubmed.ncbi.nlm.nih.gov/38777667/

[39] Kumana ET, Charles WN, Milton-Jones H, Agbontaen K, Soussi S, Dunn K, et al. "Evaluating inter-and intra-rater reliability in the bronchoscopic grading of burn inhalation injury: The iBRONCH-BII study." Burns : journal of the International Society for Burn Injuries 2025. PMID: 40327969. https://pubmed.ncbi.nlm.nih.gov/40327969/

[40] Zhang K, Singh S. "Deep learning framework for bronchoscopic diagnosis of burn inhalation injury." Burns : journal of the International Society for Burn Injuries 2026. PMID: 41297238. https://pubmed.ncbi.nlm.nih.gov/41297238/

[41] Schall GL, McDonald HD, Carr LB, Capozzi A. "Xenon ventilation-perfusion lung scans. The early diagnosis of inhalation injury." JAMA 1978. PMID: 712935. https://pubmed.ncbi.nlm.nih.gov/712935/

[42] Lund T, Goodwin CW, McManus WF, Shirani KZ, Stallings RJ, Mason AD, et al. "Upper airway sequelae in burn patients requiring endotracheal intubation or tracheostomy." Annals of surgery 1985. PMID: 3883921. https://pubmed.ncbi.nlm.nih.gov/3883921/

[43] Zawacki BE, Azen SP, Imbus SH, Chang YT. "Multifactorial probit analysis of mortality in burned patients." Annals of surgery 1979. PMID: 758852. https://pubmed.ncbi.nlm.nih.gov/758852/

[44] Badulak JH, Schurr M, Sauaia A, Ivashchenko A, Peltz E. "Defining the criteria for intubation of the patient with thermal burns." Burns : journal of the International Society for Burn Injuries 2018. PMID: 29548862. https://pubmed.ncbi.nlm.nih.gov/29548862/

[45] Freno D, Sahawneh J, Harrison S, Sahawneh T, Patterson S, Kahn SA. "Determining the role of nasolaryngoscopy in the initial evaluation for upper airway injury in patients with facial burns." Burns : journal of the International Society for Burn Injuries 2018. PMID: 29122412. https://pubmed.ncbi.nlm.nih.gov/29122412/

[46] Chotalia M, Pirrone C, Mangham T, Torlinska B, Mullhi R, England K, et al. "The Predictive Applicability of Liberal vs Restrictive Intubation Criteria in Adult Patients With Suspected Inhalation Injury-A Retrospective Cohort Study." Journal of burn care & research : official publication of the American Burn Association 2020. PMID: 32504540. https://pubmed.ncbi.nlm.nih.gov/32504540/

[47] Perkins L, Horita H, Adams L, Marshall W, Lee J, Doucet J, et al. "Inhalation Injury: Which Providers Can Assess the Need for Intubation?." Journal of burn care & research : official publication of the American Burn Association 2023. PMID: 37208913. https://pubmed.ncbi.nlm.nih.gov/37208913/

[48] Smith MD, April MD, Schauer SG, Rizzo JA. "Repeat Bronchoscopies Are Poorly Predictive of Outcomes Following Inhalation Injury." Journal of burn care & research : official publication of the American Burn Association 2025. PMID: 38628143. https://pubmed.ncbi.nlm.nih.gov/38628143/

[49] Endorf FW, Gamelli RL. "Inhalation injury, pulmonary perturbations, and fluid resuscitation." Journal of burn care & research : official publication of the American Burn Association 2007. PMID: 17211205. https://pubmed.ncbi.nlm.nih.gov/17211205/

[50] Stanton EW, Wang S, Han K, Nevarez C, Srihari P, Yenikomshian HA, et al. "Hydroxocobalamin is not associated with methemoglobinemia in patients with inhalation injury and suspected cyanide toxicity and a proposed algorithm for hydroxocobalamin administration." Burns : journal of the International Society for Burn Injuries 2024. PMID: 38760187. https://pubmed.ncbi.nlm.nih.gov/38760187/

[51] Cartotto RC, Innes M, Musgrave MA, Gomez M, Cooper AB. "How well does the Parkland formula estimate actual fluid resuscitation volumes?." The Journal of burn care & rehabilitation 2002. PMID: 12142578. https://pubmed.ncbi.nlm.nih.gov/12142578/

[52] Halgas B, Bay C, Neagoe A, Richey K, Hofmann L, Foster K. "Associationbetween hyperoxia and mortality in severely burned patients." Burns : journal of the International Society for Burn Injuries 2020. PMID: 32600936. https://pubmed.ncbi.nlm.nih.gov/32600936/

[53] Sanders KN, Aggarwal J, Stephens JM, Michalopoulos SN, Dalton D, Lewis DE, et al. "Cost impact of hydroxocobalamin in the treatment of patients with known or suspected cyanide poisoning due to smoke inhalation from closed-space fires." Burns : journal of the International Society for Burn Injuries 2022. PMID: 34903402. https://pubmed.ncbi.nlm.nih.gov/34903402/

[54] Lopez E, Fujiwara O, Lima-Lopez F, Suman OE, Mlcak RP, Hawkins HK, et al. "Nebulized Epinephrine Limits Pulmonary Vascular Hyperpermeability to Water and Protein in Ovine With Burn and Smoke Inhalation Injury." Critical care medicine 2016. PMID: 26465218. https://pubmed.ncbi.nlm.nih.gov/26465218/

[55] Jonkam C, Zhu Y, Jacob S, Rehberg S, Kraft E, Hamahata A, et al. "Muscarinic receptor antagonist therapy improves acute pulmonary dysfunction after smoke inhalation injury in sheep." Critical care medicine 2010. PMID: 20838334. https://pubmed.ncbi.nlm.nih.gov/20838334/

[56] Miller AC, Rivero A, Ziad S, Smith DJ, Elamin EM. "Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury." Journal of burn care & research : official publication of the American Burn Association 2009. PMID: 19165116. https://pubmed.ncbi.nlm.nih.gov/19165116/

[57] Cox CL, McIntire AM, Bolton KJ, Foster DR, Fritschle AC, Harris SA, et al. "A Multicenter Evaluation of Outcomes Following the Use of Nebulized Heparin for Inhalation Injury (HIHI2 Study)." Journal of burn care & research : official publication of the American Burn Association 2020. PMID: 32594168. https://pubmed.ncbi.nlm.nih.gov/32594168/

[58] Sang L, Guo X, Zhao Y, Shi J, Niu Z, Wu Z, et al. "Protective Effect of Nebulized Heparin in the Animal Models of Smoke Inhalation Injury: A Meta-analysis and Systematic Review of Experimental Studies." Journal of burn care & research : official publication of the American Burn Association 2023. PMID: 36269755. https://pubmed.ncbi.nlm.nih.gov/36269755/

[59] Tasaki O, Mozingo DW, Dubick MA, Goodwin CW, Yantis LD, Pruitt BA. "Effects of heparin and lisofylline on pulmonary function after smoke inhalation injury in an ovine model." Critical care medicine 2002. PMID: 11998809. https://pubmed.ncbi.nlm.nih.gov/11998809/

[60] Cioffi WG, Rue LW, Graves TA, McManus WF, Mason AD, Pruitt BA. "Prophylactic use of high-frequency percussive ventilation in patients with inhalation injury." Annals of surgery 1991. PMID: 2039288. https://pubmed.ncbi.nlm.nih.gov/2039288/

[61] Cortiella J, Mlcak R, Herndon D. "High frequency percussive ventilation in pediatric patients with inhalation injury." The Journal of burn care & rehabilitation 1999. PMID: 10342478. https://pubmed.ncbi.nlm.nih.gov/10342478/

[62] Reper P, Wibaux O, Van Laeke P, Vandeenen D, Duinslaeger L, Vanderkelen A. "High frequency percussive ventilation and conventional ventilation after smoke inhalation: a randomised study." Burns : journal of the International Society for Burn Injuries 2002. PMID: 12163294. https://pubmed.ncbi.nlm.nih.gov/12163294/

[63] Miller AC, Ferrada PA, Kadri SS, Nataraj-Bhandari K, Vahedian-Azimi A, Quraishi SA. "High-Frequency Ventilation Modalities as Salvage Therapy for Smoke Inhalation-Associated Acute Lung Injury: A Systematic Review." Journal of intensive care medicine 2018. PMID: 28651475. https://pubmed.ncbi.nlm.nih.gov/28651475/

[64] Allan PF, Osborn EC, Chung KK, Wanek SM. "High-frequency percussive ventilation revisited." Journal of burn care & research : official publication of the American Burn Association 2010. PMID: 20616646. https://pubmed.ncbi.nlm.nih.gov/20616646/

[65] Glas GJ, Horn J, van der Hoeven SM, Hollmann MW, Cleffken B, Colpaert K, et al. "Changes in ventilator settings and ventilation-induced lung injury in burn patients-A systematic review." Burns : journal of the International Society for Burn Injuries 2020. PMID: 31202528. https://pubmed.ncbi.nlm.nih.gov/31202528/

[66] Akın M, Tuncer HB, Akgün AE, Erkılıç E. "New Treatment Modality for Burn Injury-Related Acute Respiratory Distress Syndrome: High-Flow Nasal Oxygen Therapy in Major Burns." Journal of burn care & research : official publication of the American Burn Association 2024. PMID: 38630547. https://pubmed.ncbi.nlm.nih.gov/38630547/

[67] Szentgyorgyi L, Shepherd C, Dunn KW, Fawcett P, Barker JM, Exton P, et al. "Extracorporeal membrane oxygenation in severe respiratory failure resulting from burns and smoke inhalation injury." Burns : journal of the International Society for Burn Injuries 2018. PMID: 29500117. https://pubmed.ncbi.nlm.nih.gov/29500117/

[68] Heng X, Cai P, Yuan Z, Peng Y, Luo G, Li H. "Efficacy and safety of extracorporeal membrane oxygenation for burn patients: a comprehensive systematic review and meta-analysis." Burns & trauma 2023. PMID: 36873286. https://pubmed.ncbi.nlm.nih.gov/36873286/

[69] Peters RA, Cancio JM, Glenn K, Cancio LC. "Extracorporeal Membrane Oxygenation in a Patient with Severe Inhalation Injury: Multidisciplinary Burn Team Care." Journal of burn care & research : official publication of the American Burn Association 2024. PMID: 38367208. https://pubmed.ncbi.nlm.nih.gov/38367208/

[70] Dhanani J, Pincus J, Townsend S, Pang G, Vujcich E, Windsor M, et al. "Delayed Tracheoesophageal Fistula and Refractory Respiratory Failure Caused by Inhalation Burns and Emergency Venovenous ECMO to Facilitate Its Management: A Case Report." Journal of burn care & research : official publication of the American Burn Association 2023. PMID: 36941770. https://pubmed.ncbi.nlm.nih.gov/36941770/

[71] Tsuchiya A, Yamana H, Kawahara T, Tsutsumi Y, Matsui H, Fushimi K, et al. "Tracheostomy and mortality in patients with severe burns: A nationwide observational study." Burns : journal of the International Society for Burn Injuries 2018. PMID: 29980328. https://pubmed.ncbi.nlm.nih.gov/29980328/

[72] Kubo T, Osuka A, Kabata D, Kimura M, Tabira K, Ogura H. "Chest physical therapy reduces pneumonia following inhalation injury." Burns : journal of the International Society for Burn Injuries 2021. PMID: 32711901. https://pubmed.ncbi.nlm.nih.gov/32711901/

[73] Keramati M, Srivastava A, Sakabu S, Rumbolo P, Smock M, Pollack J, et al. "The Wittmann Patch s a temporary abdominal closure device after decompressive celiotomy for abdominal compartment syndrome following burn." Burns : journal of the International Society for Burn Injuries 2008. PMID: 17949916. https://pubmed.ncbi.nlm.nih.gov/17949916/

[74] Santos RM, Boyd AN, Walroth TA, Hall A, King J, Ahiskali A, et al. "A Multicenter, Retrospective Outcome Analysis of Vancomycin Area Under the Curve Versus Trough-Based Dosing Strategies in Patients With Burn OR Inhalational Injuries (MONITOR)." Journal of burn care & research : official publication of the American Burn Association 2024. PMID: 38900835. https://pubmed.ncbi.nlm.nih.gov/38900835/

[75] Huang S, Wang D, Ma Q, Shen T, Min D, Wang Y, et al. "Early coagulation changes as predictors of adverse outcomes in patients with severe burn and inhalation injuries." Burns : journal of the International Society for Burn Injuries 2025. PMID: 39813895. https://pubmed.ncbi.nlm.nih.gov/39813895/

[76] Reid A, Ha JF. "Inhalational injury and the larynx: A review." Burns : journal of the International Society for Burn Injuries 2019. PMID: 30529118. https://pubmed.ncbi.nlm.nih.gov/30529118/

[77] Khadim MF, Rashid A, Fogarty B, Khan K. "Mortality estimates in the elderly burn patients: the Northern Ireland experience." Burns : journal of the International Society for Burn Injuries 2009. PMID: 18687531. https://pubmed.ncbi.nlm.nih.gov/18687531/

[78] Jones CD, Ho W, Gunn E, Widdowson D, Bahia H. "E-cigarette burn injuries: Comprehensive review and management guidelines proposal." Burns : journal of the International Society for Burn Injuries 2019. PMID: 30442380. https://pubmed.ncbi.nlm.nih.gov/30442380/

[79] Kirkpatrick JJ, Enion DS, Burd DA. "Hydrofluoric acid burns: a review." Burns : journal of the International Society for Burn Injuries 1995. PMID: 8540973. https://pubmed.ncbi.nlm.nih.gov/8540973/

[80] Alshammari SM, Almarzouq S, Alghamdi AA, Shash H. "Mortality and Survival Analysis of Burn Patients Admitted in a Critical Care Burn Unit, Saudi Arabia." Saudi journal of medicine & medical sciences 2022. PMID: 36247064. https://pubmed.ncbi.nlm.nih.gov/36247064/

[81] Buckley CT, Smith RR, Velamuri SR, Hill DM. "A Comprehensive, Retrospective Analysis of Variables for Potential Mortality Impact in Patients With Thermal or Inhalation Injury." Journal of burn care & research : official publication of the American Burn Association 2023. PMID: 35639813. https://pubmed.ncbi.nlm.nih.gov/35639813/

[82] Sheppard NN, Hemington-Gorse S, Shelley OP, Philp B, Dziewulski P. "Prognostic scoring systems in burns: a review." Burns : journal of the International Society for Burn Injuries 2011. PMID: 21940104. https://pubmed.ncbi.nlm.nih.gov/21940104/

[83] Wier J, Hulsebos I, Spera L, Yenikomshian H, Gillenwater J. "Long-Term Pulmonary Sequelae After Inhalation Injury: A Retrospective Case-Control Study." Journal of burn care & research : official publication of the American Burn Association 2023. PMID: 34216469. https://pubmed.ncbi.nlm.nih.gov/34216469/

[84] Clayton NA, Hall J, Ward EC, Kol MR, Maitz PK. "Clinical profile and recovery pattern of dysphonia following inhalation injury: A 10-year review." Burns : journal of the International Society for Burn Injuries 2025. PMID: 39721235. https://pubmed.ncbi.nlm.nih.gov/39721235/

[85] Dries DJ, Endorf FW. "Inhalation injury: epidemiology, pathology, treatment strategies." Scandinavian journal of trauma, resuscitation and emergency medicine 2013. PMID: 23597126. https://pubmed.ncbi.nlm.nih.gov/23597126/

[86] Dyamenahalli K, Garg G, Shupp JW, Kuprys PV, Choudhry MA, Kovacs EJ. "Inhalation Injury: Unmet Clinical Needs and Future Research." Journal of burn care & research : official publication of the American Burn Association 2019. PMID: 31214710. https://pubmed.ncbi.nlm.nih.gov/31214710/

[87] Fedor CJ, Arellano JA, Liu HY, Kaulakis MG, Corcos AC, Siedsma MP, et al. "Clearing the Air: Impact of COPD on Inhalation Injury Outcomes." Journal of burn care & research : official publication of the American Burn Association 2025. PMID: 40483684. https://pubmed.ncbi.nlm.nih.gov/40483684/

[88] Weng YT, Tsai YC, Cherng JH, Wang CH, Tzeng YS, Ou KL, et al. "Impact of a newly implemented burn protocol at Tri-Service General Hospital: Outcome analysis of 20-year experience." Burns : journal of the International Society for Burn Injuries 2025. PMID: 39522371. https://pubmed.ncbi.nlm.nih.gov/39522371/

[89] Levine BA, Petroff PA, Slade CL, Pruitt BA. "Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient." The Journal of trauma 1978. PMID: 347099. https://pubmed.ncbi.nlm.nih.gov/347099/

[90] Foncerrada G, Culnan DM, Capek KD, González-Trejo S, Cambiaso-Daniel J, Woodson LC, et al. "Inhalation Injury in the Burned Patient." Annals of plastic surgery 2018. PMID: 29461292. https://pubmed.ncbi.nlm.nih.gov/29461292/

[91] Jiang H, Dou Z, Chen G, Zhang G, Du W. "Insignificant Difference in Early Post-injury Gene Expression Between Patients with Burns Only and Those with Inhalation Injury: A Bioinformatics Analysis." Journal of burn care & research : official publication of the American Burn Association 2023. PMID: 37306053. https://pubmed.ncbi.nlm.nih.gov/37306053/

[92] Won YH, Cho YS, Joo SY, Seo CH. "Respiratory Characteristics in Patients With Major Burn Injury and Smoke Inhalation." Journal of burn care & research : official publication of the American Burn Association 2022. PMID: 34142710. https://pubmed.ncbi.nlm.nih.gov/34142710/

[93] Westphal M, Enkhbaatar P, Schmalstieg FC, Kulp GA, Traber LD, Morita N, et al. "Neuronal nitric oxide synthase inhibition attenuates cardiopulmonary dysfunctions after combined burn and smoke inhalation injury in sheep." Critical care medicine 2008. PMID: 18379246. https://pubmed.ncbi.nlm.nih.gov/18379246/

[94] Westphal M, Rehberg S, Maybauer MO, Maybauer DM, Enkhbaatar P, Westphal-Varghese BB, et al. "Cardiopulmonary effects of low-dose arginine vasopressin in ovine acute lung injury." Critical care medicine 2011. PMID: 21057315. https://pubmed.ncbi.nlm.nih.gov/21057315/

[95] Hamahata A, Enkhbaatar P, Sakurai H, Nozaki M, Traber DL. "Sclerosis therapy of bronchial artery attenuates acute lung injury induced by burn and smoke inhalation injury in ovine model." Burns : journal of the International Society for Burn Injuries 2010. PMID: 20381969. https://pubmed.ncbi.nlm.nih.gov/20381969/

[96] Schenarts PJ, Schmalstieg FC, Hawkins H, Bone HG, Traber LD, Traber DL. "Effects of an L-selectin antibody on the pulmonary and systemic manifestations of severe smoke inhalation injuries in sheep." The Journal of burn care & rehabilitation 2000. PMID: 10850904. https://pubmed.ncbi.nlm.nih.gov/10850904/

[97] Yang SY, Huang CJ, Yen CI, Kao YC, Hsiao YC, Yang JY, et al. "Machine learning approach for predicting inhalation injury in patients with burns." Burns : journal of the International Society for Burn Injuries 2023. PMID: 37055284. https://pubmed.ncbi.nlm.nih.gov/37055284/

[98] Shimoda K, Murakami K, Enkhbaatar P, Traber LD, Cox RA, Hawkins HK, et al. "Effect of poly(ADP ribose) synthetase inhibition on burn and smoke inhalation injury in sheep." American journal of physiology. Lung cellular and molecular physiology 2003. PMID: 12626333. https://pubmed.ncbi.nlm.nih.gov/12626333/

[99] Flinn AN, Kemp Bohan PM, Rauschendorfer C, Le TD, Rizzo JA. "Inhalation Injury Severity Score on Admission Predicts Overall Survival in Burn Patients." Journal of burn care & research : official publication of the American Burn Association 2023. PMID: 37279511. https://pubmed.ncbi.nlm.nih.gov/37279511/

[100] Dancey DR, Hayes J, Gomez M, Schouten D, Fish J, Peters W, et al. "ARDS in patients with thermal injury." Intensive care medicine 1999. PMID: 10654206. https://pubmed.ncbi.nlm.nih.gov/10654206/

[101] Zhi L, Wang X, Pan X, Han C. "Fluid balance in the resorption stage correlates with outcomes of severe burn patients." Burns : journal of the International Society for Burn Injuries 2023. PMID: 37821273. https://pubmed.ncbi.nlm.nih.gov/37821273/

[102] Hill DM, Reger M, Todor LA, Boyd AN, Cogle S, DeWitt A, et al. "An Appraisal of Pharmacotherapy-Pertinent Literature for Clinicians Caring for Patients With Thermal or Inhalation Injury." Journal of burn care & research : official publication of the American Burn Association 2024. PMID: 38285011. https://pubmed.ncbi.nlm.nih.gov/38285011/

[103] Olszewski A, Yanes A, Stafford J, Greenhalgh DG, Palmieri TL, Sen S, et al. "Development and Implementation of an Innovative Burn Nursing Handbook for Quality Improvement." Journal of burn care & research : official publication of the American Burn Association 2016. PMID: 26284646. https://pubmed.ncbi.nlm.nih.gov/26284646/

[104] Carsin H, Assicot M, Feger F, Roy O, Pennacino I, Le Bever H, et al. "Evolution and significance of circulating procalcitonin levels compared with IL-6, TNF alpha and endotoxin levels early after thermal injury." Burns : journal of the International Society for Burn Injuries 1997. PMID: 9232281. https://pubmed.ncbi.nlm.nih.gov/9232281/